Go to Work, Ladies! Your Kids Will Be Grateful
So what if you can’t have it all? Maybe your daughter can.
A new working paper by the Harvard Business School finds that daughters of working mothers are likely to be more successful in the workplace than their peers. Analyzing data on 50,000 people in 24 countries, researchers found these women are more likely to be employed, hold supervisory positions and earn more money than women who grew up with stay-at-home mothers.
A working mother was defined as being employed before their child turned 14 years old.
Daughters of employed moms are 4.5 percent more likely than daughters of stay-at-home moms have jobs, the study found -- small but statistically significant difference, the authors say, meaning it’s not just a coincidence. Daughters of working mothers also earn 23 percent more than daughters of women did not work outside the home.
Related: 10 Best States for Working Mothers
In addition, 33 percent of daughters of employed women hold supervisory roles, compared to 25 percent of daughters of stay-at-home mothers. And the daughters of working moms do fewer hours of housework each week, the study finds.
Sons of working mothers were found to spend 7.5 more hours on childcare per week and a longer amount of time on household chores. They spend more time caring for family members than sons of stay-at-home mothers.
The study hints at the neglected importance of gender attitudes that are shaped and refined within homes and in families, since policymakers usually focus on gender differences on the political and corporate levels. Parents who embody non-traditional gender roles are serving as role models and a resource for their children who might one day enact non-traditional gender roles in their own lives.
Working mothers are demonstrating to their children that traditional gender roles are not the only opportunities for their sons or daughters. Even though many mothers worry that by working they’re neglecting their child, they could actually be helping them in the long-run by showing them they’re world might not be as limited as tradition suggests.
The study comes in the wake of a slight reversal in the decades-long trend of women joining the ranks of the employed. From 1999 to 2012, the number of mothers who were unemployed in the U.S. rose from 23 percent to 29 percent, a Pew study found. Causes of the rise are debatable, but a growing number of women cite their inability to find a job, largely as the result of the recession.
With the job market recovering, the new study’s message is clear: Lean in, women!
Chart of the Day: High Deductible Blues
The higher the deductible in your health insurance plan, the less happy you probably are with it. That’s according to a new report on employer-sponsored health insurance from the Kaiser Family Foundation and the Los Angeles Times.
Chart of the Day: Tax Cuts and the Missing Capex Boom
Despite the Republican tax overhaul, businesses aren’t significantly increasing their capital expenditures. “The federal government will have to borrow an added $1 trillion through 2027 to pay for the corporate tax breaks,” says Bloomberg’s Mark Whitehouse. “So far, it’s hard to see what the country is getting in return.”
Chart of the Day: 2019’s Lobbying Leaders
Roll Call reports that trade, infrastructure and health care issues including prescription drug prices “dominated the lobbying agendas of some of the biggest spenders on K Street early this year.” Here’s Roll Call’s look at the top lobbying spenders so far this year:
Can You Fix Social Security? A New Tool Lets You Try
The Congressional Budget Office released an interactive tool Wednesday that shows how some widely discussed policy changes would affect the long-run financial health of the Social Security system.
“This interactive tool allows the user to explore seven policy options that could be used to improve the Social Security program’s finances and delay the trust funds’ exhaustion,” CBO said. “Four options would reduce benefits, and three options would increase payroll taxes. The tool allows for any combination of those options. It also lets the user change implementation dates and choose whether to show scheduled or payable benefits. … The tool also shows the impact of the options on different groups of people.”
Click here to view the interactive tool on the CBO website.
Why Prescription Drug Prices Keep Rising – and 3 Ways to Bring Them Down
Prescription drug prices have been rising at a blistering rate over the last few decades. Between 1980 and 2016, overall spending on prescription drugs rose from about $12 billion to roughly $330 billion, while its share of total health care spending doubled, from 5% to 10%.
Although lawmakers have shown renewed interest in addressing the problem, with pharmaceutical CEOs testifying before the Senate Finance Committee in February and pharmacy benefit managers (PBMS) scheduled to do so this week, no comprehensive plan to halt the relentless increase in prices has been proposed, let alone agreed upon.
Robin Feldman, a professor at the University of California Hastings College of Law, takes a look at the drug pricing system in a new book, “Drugs, Money and Secret Handshakes: The Unstoppable Growth of Prescription Drug Prices.” In a recent conversation with Bloomberg’s Joe Nocera, Feldman said that one of the key drivers of rising prices is the ongoing effort of pharmaceutical companies to maintain control of the market.
Fearing competition from lower-cost generics, drugmakers began over the last 10 or 15 years to focus on innovations “outside of the lab,” Feldman said. These innovations include paying PBMs to reduce competition from generics; creating complex systems of rebates to PBMs, hospitals and doctors to maintain high prices; and gaming the patent system to extend monopoly pricing power.
Feldman’s research on the dynamics of the drug market led her to formulate three general solutions for the problem of ever-rising prices:
1) Transparency: The current system thrives on secret deals between drug companies and middlemen. Transparency “lets competitors figure out how to compete and it lets regulators see where the bad behaviors occur,” Feldman says.
2) Patent limitations: Drugmakers have become experts at extending patents on existing drugs, often by making minor modifications in formulation, dosage or delivery. Feldman says that 78% of drugs getting new patents are actually old drugs gaining another round of protection, and thus another round of production and pricing exclusivity. A “one-and-done” patent system would eliminate this increasingly common strategy.
3) Simplification: Feldman says that “complexity breeds opportunity,” and warns that the U.S. “drug price system is so complex that the gaming opportunities are endless.” While “ruthless simplification” of regulatory rules and approval systems could help eliminate some of those opportunities, Feldman says that the U.S. doesn’t seem to be moving in this direction.
Read the full interview at Bloomberg News.